These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1289 related articles for article (PubMed ID: 28097159)

  • 1. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
    Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
    J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.
    D'Amato G; Liccardi G; Noschese P; Salzillo A; D'Amato M; Cazzola M
    Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):227-9. PubMed ID: 15379589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of anti-IgE therapy beyond allergic asthma.
    Stokes JR; Casale TB
    J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.
    Félix Toledo R; Negro Alvarez JM; Miralles López JC
    Allergol Immunopathol (Madr); 2002; 30(2):94-9. PubMed ID: 11958741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dermatological implications of omalizumab, an anti-IgE antibody].
    Di Lucca-Chrisment J
    Rev Med Suisse; 2015 Apr; 11(468):779-80, 782-3. PubMed ID: 26021140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab in children.
    Licari A; Marseglia A; Caimmi S; Castagnoli R; Foiadelli T; Barberi S; Marseglia GL
    Paediatr Drugs; 2014 Dec; 16(6):491-502. PubMed ID: 25404353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab in the treatment of chronic urticaria.
    Francés L; Leiva-Salinas M; Silvestre JF
    Actas Dermosifiliogr; 2014; 105(1):45-52. PubMed ID: 23938072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab.
    Easthope S; Jarvis B
    Drugs; 2001; 61(2):253-60; discussion 261. PubMed ID: 11270941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-IgE--emerging opportunities for Omalizumab.
    Babu KS; Polosa R; Morjaria JB
    Expert Opin Biol Ther; 2013 May; 13(5):765-77. PubMed ID: 23517576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology.
    Mauro M; Incorvaia C; Formigoni C; Elia R; Russello M; Pellegrino D
    Panminerva Med; 2012 Dec; 54(4):305-12. PubMed ID: 23123583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-IgE monoclonal antibody: a new approach to the treatment of allergic respiratory diseases.
    D'Amato G; Oldani V; Donner CF
    Monaldi Arch Chest Dis; 2003; 59(1):25-9. PubMed ID: 14533279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-IgE antibodies for the treatment of asthma.
    Buhl R
    Curr Opin Pulm Med; 2005 Jan; 11(1):27-34. PubMed ID: 15591885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab, an anti-immunoglobulin E antibody: state of the art.
    Incorvaia C; Mauro M; Russello M; Formigoni C; Riario-Sforza GG; Ridolo E
    Drug Des Devel Ther; 2014; 8():197-207. PubMed ID: 24532966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST; Djukanović R; Casale T; Bousquet J
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab beyond asthma.
    Sanchez J; Ramirez R; Diez S; Sus S; Echenique A; Olivares M; Cardona R
    Allergol Immunopathol (Madr); 2012; 40(5):306-15. PubMed ID: 22264640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab in asthma: an update on recent developments.
    Humbert M; Busse W; Hanania NA; Lowe PJ; Canvin J; Erpenbeck VJ; Holgate S
    J Allergy Clin Immunol Pract; 2014; 2(5):525-36.e1. PubMed ID: 25213045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery and development of omalizumab for the treatment of asthma.
    Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
    Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.